Orphan Disease Biotech Fate Therapeutics Files for a $69 Million IPO

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Fate Therapeutics, a clinical-stage biotech developing stem cell treatments for orphan diseases, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering.

http://www.biospace.com/news_story.aspx?StoryID=305885&full=1